10103-GMC-7 RETROSPECTIVE ANALYSIS ABOUT BEVACIZUMAB THERAPY FOR 10 YEARS AFTER AUTHORIZATION FOR MALIGNANT GLIOMAS IN OUR DEPARTMENT

Abstract

In the treatment of malignant gliomas, drug therapy options are limited, and the Stupp regimen is still the standard treatment, In 2013, bevacizumab (BEV) was approved and became an option. Although BEV is not considered to prolong survival, it is currently used in many cases. We conducted a retrospective review of the use of BEV in our department 10 years after its approval. Of the 83 cases treated at our department, 70 were treated from the initial treatment to death or transfer to BSC. 70 cases consisted of 39 males and 31 females with a mean age of 63 years. Pathology was obtained in 69, and the diagnosis was made according to the WHO classification at each treated time. In the 21 cases where BEV was initially used, biopsy was performed in 13 cases and partial excision in 3 cases, indicating that BEV tended to be used from the time of initial presentation if there was residual disease. Of the 38 cases used at recurrence, 29 were treated with BEV alone, 8 with surgery followed by BEV for residual disease, and 6 of the 70 cases were still being followed. Of the remaining 64 patients, 55 died and 9 were transferred to BSC. The average number of times was 9.6 times, and the reasons for termination were invalidity in 45 cases, side effects in 10 cases, BSC transfer in 6 cases, patient request in 2 cases, and unknown in 1 case. In the 55 patients who died, the average overall survival was 21.4 months, the average survival time from the start of BEV to death was 8.9 months, and the average survival time from the end of BEV to death was 3.3 months. Based on 10 years of experience, it is necessary to find more efficient ways to use BEV.